TD Cowen lifts McKesson PT to Street-high after drug distributor raises forecast
** TD Cowen raised drug distributor McKesson's MCK.N PT from $830 to a Street-high of $864
** New PT represents an 16.5% upside to the stock's last close
** Brokerage sees upside for MCK, citing a stronger outlook for North America pharma and oncology/multispecialty and the lift to long‑term adjusted EPS targets
** TD Cowen says that since biosimilar interchangeability is not currently factored into MCK's guide it presents substantial upside
** Biosimilar interchangeability means a copy of a biologic medicine can be swapped in at the pharmacy for the original without the doctor needing to change the prescription, because it's proven to work the same and be just as safe
** At least six brokerages raised their PT after MCK raised its annual profit forecast on Tuesday
** As of last close, MCK stock was up ~31% YTD
Related Articles
H-1B Policy Shock: Challenges for the Tech Industry and U.S. Stock Market Investments
TradingKey - The H-1B visa allows foreign professionals to work legally in the United States, primarily targeting talent in science, technology, engineering, and mathematics (STEM) fields.
U.S. August PCE: Inflation Remains the Market's Greatest Risk
Our baseline forecast anticipates sustained asset price increases. However, if inflation surpasses market expectations in the coming months, it could hinder further rate cuts and pose the greatest risk to financial markets.
Memory Giant Micron Delivers Stellar Q4 FY2025 with Explosive DRAM and HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) delivered a stellar Q4 FY2025 earnings report, exceeding expectations on revenue, earnings, and margins. The company reported total revenue of $11.32 billion, up 46% YoY and 22% sequentially, surpassing the consensus forecast of $11.1 billion.
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.
